Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study
Por:
Butzkueven, H, Farr, P, Ozakbas, S, Boz, C, Kalincik, T, Taylor, L, Van Der Walt, A, Alroughani, R, Buzzard, K, Skibina, O, Lechner-Scott, J, Laureys, G, Terzi, M, Van Pesch, V, Grand-Maison, F, Barnett, M, Kermode, A, Menoyo, JLS, Rojas, J, Willekens, B, Foschi, M, Ramo-Tello, C, Skromne, E, Dirks, P, Muros-Le Rouzic, E and Spelman, T
Publicada:
1 feb 2026
Ahead of Print:
1 dic 2025
Resumen:
Introduction: The MSOCR-R study evaluates the long-term effectiveness of ocrelizumab (OCR) in patients with relapsing multiple sclerosis (RMS) in real-world clinical settings. Methods: MSOCR-R is an ongoing, prospective, longitudinal, observational cohort study of people with RMS newly treated with OCR, using data from the international MSBase registry. The study started in July 2018, and data collected up to October 2023 were analyzed. Outcomes were confirmed disability worsening (CDW), progression independent of relapses (PIRA), and no evidence of disease activity (NEDA-3: absence of relapse, 24-week CDW, or imaging activity). Results: Overall, 1011 patients were enrolled (18.1% initiated OCR first-line therapy; 81.9% switched from previous treatment), with a median time of 3.4 years on OCR treatment. About 67% of patients were females. At OCR initiation, mean age was 41.9 years, median disease duration was 10.4 years, and median Expanded Disability Status Scale score was 3.0. The 4-year Kaplan-Meier probabilities of 24-week CDW or PIRA were 25.2% (95% CI 21.6-29.1) and 21.9% (95% CI 18.3-25.2), respectively. Annualized relapse rate substantially decreased from 0.58 (95% CI 0.53-0.63) before OCR to 0.05 (95% CI 0.04-0.06) after treatment initiation. NEDA-3 was assessed in 366 patients and the probability of achieving NEDA-3 was 39.7% (95% CI 36.0-43.5) at 4 years. Persistence on OCR was 88.0% (95% CI, 85.2-90.3) at 4 years. Better clinical outcomes were consistently observed among the first-line treatment cohort. Conclusion: The MSOCR-R study provides strong real-world evidence of OCR effectiveness in people with RMS.
Filiaciones:
Butzkueven, H:
Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Australia
Alfred Ctr, MSBase Fdn, Melbourne, Australia
Farr, P:
Alfred Ctr, MSBase Fdn, Melbourne, Australia
Ozakbas, S:
Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye
Boz, C:
Karadeniz Tech Univ, Med Fac, Dept Neurol, Trabzon, Turkiye
Kalincik, T:
Univ Melbourne, Dept Med, CORE, Melbourne, Australia
Royal Melbourne Hosp, Neuroimmunol Ctr, Melbourne, Australia
Taylor, L:
Univ Melbourne, Dept Med, CORE, Melbourne, Australia
Van Der Walt, A:
Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Australia
Alfred Ctr, MSBase Fdn, Melbourne, Australia
Alroughani, R:
Amiri Hosp, Qurtoba, Sharq, Kuwait
Buzzard, K:
Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Dept Neurosci, Box Hill, Australia
Skibina, O:
Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Dept Neurosci, Box Hill, Australia
Lechner-Scott, J:
Univ Newcastle, Newcastle, Australia
Laureys, G:
Ghent Univ Hosp, Ghent, Belgium
Terzi, M:
Ondokuz Mayis Univ, Med Fac, Dept Neurol, Samsun, Turkiye
Van Pesch, V:
Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium
Grand-Maison, F:
Neuro Rive Sud, Greenfield Pk, PQ, Canada
Barnett, M:
Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia
Kermode, A:
Univ Western Australia, Nedlands, Australia
Menoyo, JLS:
Hosp Galdakao Usansolo, Galdakao, Spain
Rojas, J:
Hosp Univ CEM, Buenos Aires, Argentina
Willekens, B:
Antwerp Univ Hosp, Edegem, Belgium
Foschi, M:
AUSL Romagna, S Maria Croci Hosp, Dept Neurosci, MS Ctr,Neurol Unit, Ravenna, Italy
:
Hosp Badalona Germans Trias & Pujol, Badalona, Spain
Skromne, E:
Hosp Angeles Lomas, Inst Mexicano Neurociencias, Valle De Las Palmas, Mexico
Dirks, P:
F Hoffmann La Roche Ltd, Basel, Switzerland
Muros-Le Rouzic, E:
F Hoffmann La Roche Ltd, Basel, Switzerland
Spelman, T:
Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
Green Published, hybrid
|